BRAF and melanoma: As expected, SK-MEL-173 is barely sensitive to knockdown of BRAF, since it carries an activating NRAS mutation, which may provide compensatory proliferation and survival stimulation via the PI3K pathway [23], causing the SK-MEL-173 cells to be less dependent on the MAPK signaling pathway than the other melanoma cell lines.